Last reviewed · How we verify
Autologous T Cells Redirected to GPC3 for Treating Patients With Advanced HCC
The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize glypican-3 (GPC3) is safe and effective for patients with relapsed or refractory hepatocellular carcinoma (HCC).
Details
| Lead sponsor | RenJi Hospital |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 13 |
| Start date | 2015-03 |
| Completion | 2018-11 |
Conditions
- Hepatocellular Carcinoma
Interventions
- anti-GPC3 CAR T
Primary outcomes
- Adverse events attributed to the administration of the anti-GPC3 CAR T cells — 2 years
Countries
China